Special Issue

Advances in Anti-EGFR Therapy of Metastatic Colorectal Cancer

Message from the Guest Editor

The aim of this Special Issue is to describe the innovative and less explored topics concerning the anti-EGFR treatment of mCRC, focusing on the following:

- EGFR inhibition in mCRC—beyond the antibodiesbased therapy;
- Genetic profiling of the EGFR pathway—new approaches to ameliorate patient selection;
- Links between anti-EGFR treatments and immune system activation.

One review on "where do we stand and where do we go" is also welcome.

Guest Editor

Dr. Guglielmo Nasti

Department of Abdominal Oncology, Istituto Nazionale Tumori di Napoli, IRCCS "G Pascale", Naples, Italy

Deadline for manuscript submissions

closed (15 September 2021)



Cells

an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 10.5 Indexed in PubMed



mdpi.com/si/65526

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells





Cells

an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 10.5 Indexed in PubMed



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. Cells encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).

